Allegion plc·4

Jul 27, 4:12 PM ET

Wagnes Michael J. 4

4 · Allegion plc · Filed Jul 27, 2026

Research Summary

AI-generated summary of this filing

Updated

Allegion (ALLE) CFO Michael Wagnes Exercises Options, Sells Shares

What Happened

  • Michael J. Wagnes, Allegion’s Senior Vice President and Chief Financial Officer, exercised stock options and sold the underlying shares on July 23, 2026. He exercised 1,716 options at a $71.83 strike (cash paid $123,269) and 1,468 options at an $86.93 strike (cash paid $127,613). Those 3,184 shares were then sold in the open market the same day at $150.98 per share for total gross proceeds of $259,082 and $221,639, respectively (total ≈ $480,721). The filings show the exercise/conversion of the derivative options (reported with $0 sale price in the filing format) alongside the open-market sales.

Key Details

  • Transaction date: July 23, 2026.
  • Exercises: 1,716 shares @ $71.83 (cost $123,269); 1,468 shares @ $86.93 (cost $127,613).
  • Sales: 1,716 shares @ $150.98 (proceeds $259,082); 1,468 shares @ $150.98 (proceeds $221,639). Total sale proceeds ≈ $480,721.
  • Transaction codes: M = option exercise/conversion; S = open-market sale.
  • Reported under Rule 10b5-1 trading plans (adopted Sept 12, 2025) for both the exercises and the sales (Footnotes F1, F2).
  • Option grant/vest info: footnotes note the options vested in prior years and are exercisable (F3, F4).
  • Shares owned after the transaction: not provided in the supplied Form 4 excerpt.
  • Filing timeliness: Form 4 filed July 27, 2026 for trades on July 23, 2026 (filed within the required reporting window).

Context

  • This was effectively an exercise-and-sell (cashless-style) transaction: options were exercised and the resulting shares were sold the same day. Such patterns are commonly executed to monetize vested options and, when done under a pre-established 10b5-1 plan, are pre-scheduled trades rather than ad hoc sales.
  • The presence of $0 "disposed" derivative lines reflects reporting conventions for option exercises/conversions; they do not represent a cash sale price for the exercised options themselves.

Insider Transaction Report

Form 4
Period: 2026-07-23
Transactions
  • Exercise/Conversion

    Ordinary Shares

    [F1]
    2026-07-23$71.83/sh+1,716$123,26933,015 total
  • Sale

    Ordinary Shares

    [F2]
    2026-07-23$150.98/sh1,716$259,08231,299 total
  • Exercise/Conversion

    Ordinary Shares

    [F1]
    2026-07-23$86.93/sh+1,468$127,61332,767 total
  • Sale

    Ordinary Shares

    [F2]
    2026-07-23$150.98/sh1,468$221,63931,299 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1][F3]
    2026-07-231,7160 total
    Exercise: $71.83Exp: 2027-02-13Ordinary Shares (1,716 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1][F4]
    2026-07-231,4680 total
    Exercise: $86.93Exp: 2028-02-22Ordinary Shares (1,468 underlying)
Footnotes (4)
  • [F1]The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.
  • [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.
  • [F3]A stock option that vested in equal annual installments on February 13, 2018, February 13, 2019, and February 13, 2020, and is exercisable.
  • [F4]A stock option that vested in equal annual installments on February 22, 2019, February 22, 2020, and February 22, 2021, and is exercisable.
Signature
/s/ Tandra M. Foster, Attorney-In-Fact|2026-07-27

Documents

1 file
  • 4
    wk-form4_1785183125.xmlPrimary

    FORM 4